A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently available drugs often fail to eradicate the virus from the body. Gene-editing therapies — which
